NCT01199640View on ClinicalTrials.gov

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

October 31, 2007

Conditions
Multiple Sclerosis
Interventions
DRUG

MLN1202

Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY